Several inhibitory effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on inflammasome activity in diabetes mellitus with cardiovascular disease or DKD have been suggested [306,307]. This evidence concerns the gene SLC5A2 and diabetes mellitus.